11.98

3.99% 0.46

Pre-market: 11.96 -0.02 -0.17%

Sellas Life Sciences Group Inc (SLS)

Overview News Price History Option Chain Financials Why SLS Down? Discussions Forecast Stock Split

Sellas Life Sciences Group Inc stock is traded at $11.98, with a volume of 4.62M. It is up +3.99% in the last 24 hours and down -16.37% over the past month. SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Previous Close:

$11.52

Open:

$11.43

24h Volume:

4.62M

Relative Volume:

0.57

Market Cap:

$2.42B

Revenue:

Net Income/Loss:

$-29.46M

P/E Ratio:

-52.47

EPS:

-0.2283

Net Cash Flow:

$-28.17M

1W Performance:

+3.90%

1M Performance:

-16.37%

6M Performance:

+139.84%

1Y Performance:

+634.97%

1-Day Range:

$11.10

$12.04

1-Week Range:

$11.06

$12.14

52-Week Range:

$1.39

$15.88

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Name

Sellas Life Sciences Group Inc

Sector

Healthcare (1068)

Industry

Biotechnology (595)

Phone

(646) 200-5278

Address

7 TIMES SQUARE, NEW YORK, NY

Employee

Twitter

Next Earnings Date

2026-11-11

Latest SEC Filings

SLS's Discussions on Twitter

Compare SLS vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLS Sellas Life Sciences Group Inc	11.98	2.42B	0	-29.46M	-28.17M	-0.2283
VRTX Vertex Pharmaceuticals Inc	522.38	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	796.02	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	194.82	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	962.22	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	199.86	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-21-21	Initiated	Cantor Fitzgerald	Overweight
Nov-01-18	Initiated	Oppenheimer	Outperform
Apr-02-18	Initiated	H.C. Wainwright	Buy
Mar-19-18	Upgrade	Maxim Group	Hold → Buy

Sellas Life Sciences Group Inc Stock (SLS) Latest News

12:53 PM

SLS Stock July Rout Deepens: ‘Pharma Bro’ Martin Shkreli Questions Timing Of AML Trial, Says Data May Wait Until Christmas - Stocktwits

12:53 PM

Sep 24, 2026

SLS Stock Turns Green After 3-Day Rout: Five Investors Add Shares As Key AML Trial Nears Final Trigger - Stocktwits

Sep 24, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc.SLS - PR Newswire

Sep 24, 2026

SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY - Stocktwits

Sep 24, 2026

SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results - Stocktwits

Sep 24, 2026

SLS Stock Sees Worst Day In Over A Month — But Prediction Market Flashes 83% Odds For November AML Trial Success - Stocktwits

Sep 24, 2026

SLS Stock Slips Overnight Ahead Of Pancreatic Cancer Conference — Retail Looks For Clues To SLS009’s Next Trial - Stocktwits

Sep 24, 2026

SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncology - Stocktwits

Sep 24, 2026

SLS Stock Logs Record H1 As AML Trial Nears Finish Line — Why Are Retail Traders Refusing To Cash Out? - Stocktwits

Sep 24, 2026

Sep 23, 2026

SLS Stock In Spotlight After Vanguard Capital Discloses 5.19% Stake – Retail Calls It ‘Huge Vote Of Conviction’ As AML Trial Readout Nears - Stocktwits

Sep 23, 2026

Why Did SLS, BB, OUST Stocks Surge To 52-Week Highs Today? - Stocktwits

Sep 23, 2026

SLS Stock Tracks Worst Month Since March: Investor Slashes Stake By Over 30% As Quiet Period Begins Ahead Of AML Readout - Stocktwits

Sep 23, 2026

SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation - Stocktwits

Sep 23, 2026

SLS Stock Climbs Premarket: Here’s What Smart Money Is Doing As Sellas Nears Critical Phase 3 AML Readout - Stocktwits

Sep 23, 2026

SLS Stock Edges Higher As Wall Street, Retail Expect Another MRNA Moment - Stocktwits

Sep 23, 2026

Sellas CEO Angelos Stergiou Says ‘100% Certain’ AI Can Be Used To Beat Cancer - Stocktwits

Sep 23, 2026

SLS Stock Hits Over 5-Year High: Retail Traders Bet Big On Breaking $25 As AML Readout Looms - Stocktwits

Sep 23, 2026

SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits

Sep 23, 2026

Sep 22, 2026